CRISPR Therapeutics AG (CRSP) Stock: Price, Forecast & Analyst Target
CRISPR Therapeutics AG (CRSP) — MoonshotScore 21/100 (Weak band), calculated Oct 6, 2026. Price $57.34 (+3.45%), as of the Oct 5, 2026 trading session; market cap $5.53B. Expected results Nov 9, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 2.34× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 9, 2026
CRISPR Therapeutics AG · CRSP · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: CRSP is a gene-editing biotechnology company with a portfolio of investigational therapies for blood disorders, cancers, and rare conditions using CRISPR and Cas technology. The decisive question is whether the flagship ex vivo therapy advances to approval and market adoption before cash reserves diminish.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · CRISPR Therapeutics AG (CRSP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and stalling growth. Business Quality: Poor; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Rising.
- quarterly revenue $10M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z 2.84 · Piotroski F 3
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 21 | Weak |
The score was 21 in the stored Oct 5, 2026 snapshot and remains 21 in the current publication computed Oct 6, 2026 (0); the largest pillar moves were Momentum +4 and Valuation +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $57.34 | |
| Change on the day | +3.45% | |
| 52-week range | $44.12–$78.48 | |
| Market capitalisation | $5.53B | |
| Shares traded on the day | 1.70M | |
| Beta (volatility vs the S&P 500) | 1.76 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for CRISPR Therapeutics AG (CRSP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 30, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the CRSP film — every key number, told as a short cinematic story
~2 min · open the film
What is CRISPR Therapeutics AG (CRSP), and what does it report?
Short answer · as of
CRSP develops ex vivo and in vivo gene-edited therapies targeting hemoglobinopathies, malignancies, and rare diseases.
Research dated 2026-09-13.
CRSP develops ex vivo and in vivo gene-edited therapies targeting hemoglobinopathies, malignancies, and rare diseases. The flagship ex vivo therapy modifies patients' own hematopoietic stem cells to boost fetal hemoglobin production in red blood cells for sickle cell disease and beta-thalassemia. The company pursues allogeneic CAR-T candidates and a stem cell-derived immune-evasive product for type diabetes. The income statement reflects a pre-revenue biotech model: revenues minimal, operating expenses substantial, with burn driven by clinical programs and development infrastructure.
Partnerships with Bayer, Vertex, and others provide capital infusions and potentially offset some burn, but do not materially reduce cash consumption needs. The path to profitability requires the lead program or another candidate to reach market and generate significant royalties or milestone payments.
What do the latest results show for CRISPR Therapeutics AG (CRSP)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $10M.
Research dated 2026-09-13.
Recent quarters show losses have tightened from prior periods, with the most recent quarter missing earnings expectations narrowly while revenue came in ahead of forecast, an unusual outcome for pre-revenue biotech. This improvement reflects operational discipline in spending and, crucially, the beginning of royalty revenue from partnership arrangements. The gross margin on limited revenue is highly positive, a signal that when scale arrives, unit economics will be favorable.
The near-term catalyst is regulatory progress on the lead program. Evidence of approval momentum or expanded partnership payments would improve burn and extend runway. Conversely, a clinical setback or partner de-emphasis would pressure the timeline and valuation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $64.95M Jun 30, 2026
- Latest quarter · SG&A
- $15.45M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$114.80M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Provider row rejected | $64.95M | $15.45M | −$114.80M |
| Mar 31, 2026 | $1.46M | $68.57M | $17.18M | −$130.25M |
| Dec 31, 2025 | $864,000 | $77.86M | $18.40M | −$154.76M |
| Sep 30, 2025 | $889,000 | $58.90M | $16.93M | −$132.06M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue estimate
- $7.45M Aug 3, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 3, 2026 | Provider row rejected | $7.45M | −$0.9400 | −$1.1900 |
| May 4, 2026 | $1.46M | $6.06M | −$1.2800 | −$1.1896 |
| Feb 12, 2026 | $864,000 | $4.72M | −$1.3700 | −$1.1500 |
| Nov 10, 2025 | $889,000 | $9.12M | −$1.1700 | −$1.2600 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $10M | -$91M | -$0.94 (diluted) |
| Q1 FY2026 | $1M | -$123M | -$1.28 (diluted) |
| Q4 FY2025 | $864,000 | -$131M | -$1.37 (diluted) |
| Q3 FY2025 | $889,000 | -$106M | -$1.17 (diluted) |
What are the financial strengths and risks for CRISPR Therapeutics AG (CRSP)?
Short answer
Cash and short-term investments were $2.36B at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$83.50M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The company holds substantial cash and short-term investments relative to its annual burn, providing visibility into a runway that extends several years into the future even without additional capital infusions. This cash position is a major strength in a sector where many biotech firms burn through liquidity quickly. The current ratio and quick ratio are exceptionally strong, indicating no near-term solvency pressure.
However, the path to cash flow positivity depends on program success. Debt is modest and well-covered. The distress screens show warning signs in the negative net margin and return metrics, which are expected for a pre-commercial biotech but would be concerning if cash runway tightens.
Data-derived red flags
- Negative return on equity (-30.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$83.50M Jun 30, 2026
- Previous quarter · operating cash flow
- −$108.90M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$83.50M | −$3.12M |
| Mar 31, 2026 | −$108.90M | −$500,000 |
| Dec 31, 2025 | −$92.55M | −$520,000 |
| Sep 30, 2025 | −$84.63M | −$70,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at CRISPR Therapeutics AG (CRSP)?
Short answer · as of
The next earnings report is expected on Nov 9, 2026.
Research dated 2026-09-13.
Watch for regulatory milestone announcements on the lead program, particularly topline efficacy and safety data. The company guided that capital runway extends through multiple coming years, so focus will be on development milestones, not financing urgency. Analyst estimates for profitability remain pessimistic through the decade, reflecting the probability that revenue does not materialize if trials encounter unexpected risks.
How does CRISPR Therapeutics AG compare with its peers?
Short answer
CRISPR Therapeutics AG's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Definium operates in a competitive space with multiple companies advancing mood and neurodevelopmental treatments. Differentiation rests on the specific mechanism and the trial design. The company's focus on leading programs sits against a competitive landscape including larger pharmaceutical incumbents with diversified pipelines. Scale and capitalization are asymmetric.
| Company | Price | Market value | Score |
|---|---|---|---|
| $329.17 Oct 6, 2026 | $9.87B | 98 5-pillar Oct 6, 2026 | |
| $304.69 Oct 6, 2026 | $6.15B | 96 5-pillar Oct 6, 2026 | |
| $47.85 Oct 6, 2026 | $3.80B | 96 5-pillar Oct 6, 2026 | |
| $31.76 Oct 6, 2026 | $8.54B | 90 5-pillar Oct 6, 2026 | |
| $156.58 Oct 6, 2026 | $6.40B | 69 5-pillar Oct 6, 2026 | |
| $82.60 Oct 6, 2026 | $5.09B | 68 5-pillar Oct 6, 2026 | |
| $40.23 Oct 6, 2026 | $4.34B | 66 5-pillar Oct 6, 2026 | |
| $52.85 Oct 6, 2026 | $8.18B | 65 5-pillar Oct 6, 2026 | |
| $118.00 Oct 6, 2026 | $4.97B | 64 5-pillar Oct 6, 2026 | |
| $42.03 Oct 6, 2026 | $7.17B | 64 5-pillar Oct 6, 2026 | |
| $14.46 Oct 6, 2026 | $5.10B | 62 5-pillar Oct 6, 2026 | |
| $64.80 Oct 6, 2026 | $10.7B | 56 5-pillar Oct 6, 2026 | |
| CRISPR Therapeutics AG (CRSP) — this page | $57.34 | $5.53B | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $55.00 – $80.00
- Consensus target
- $67.83
- Median target
- $68.00
Consensus record · Captured .
Measured against a quoted price of $57.34 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026
- Transactions
- 23
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 3
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 80.2% Period end Jun 30, 2026
- Previous quarter · ownership
- 80.3% Prior to period end Jun 30, 2026
- Reporting holders
- 558 Period end Jun 30, 2026
- Previous quarter · holders
- 528 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Ark Investment Management LLC | 9,460,939 |
| Blackrock, INC. | 8,348,977 |
| Orbis Allan Gray Ltd | 5,449,161 |
| Capital World Investors | 4,749,525 |
| State Street Corp | 4,321,666 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about CRISPR Therapeutics AG (CRSP)?
- Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
- CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
- Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.
Common Questions About CRSP (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is the lead ex vivo therapy?
This ex vivo gene-edited therapy modifies patients' own blood-forming stem cells to produce high levels of fetal hemoglobin, which prevents the sickling or crystallization that causes pain and organ damage in sickle cell disease and beta-thalassemia. It is the company's most advanced program and the basis of partnerships with Bayer and Vertex that provide royalty and milestone revenue. Approval and commercial launch would be transformative for CRSP's valuation and cash position. The addressable patient population is sizable but defined, so realistic expectations matter.
How long can the company operate at current burn rates?
The company has substantial cash and minimal debt, providing a runway that extends several years even without additional partnering or capital raises. The quarterly operating cash burn is in the range of hundreds of millions annualized, well below the cash on hand. However, this runway is not infinite. Acceleration of programs or increased headcount could shorten it. Conversely, additional partnership milestones or strategic capital raises could extend it indefinitely.
What are the key clinical risks?
The lead program must demonstrate durability of effect, safety over long follow-up periods, and consistent manufacturing to advance through late-stage trials. Off-target gene editing, immune responses, and manufacturing variability are known risks in the CRISPR space. Clinical trials could fail or show safety signals that limit the addressable population. The in vivo programs for liver, lung, muscle, and central nervous system disorders face additional hurdles around tissue delivery and specificity that are not yet fully solved.
Does insider activity suggest confidence in near-term progress?
Insider transactions over the recent window show sales but also grants and awards, a mix typical of pre-revenue biotech. The sales clustered around certain dates and price ranges, suggesting opportunistic trimming rather than wholesale confidence abandonment. The net of insider activity is small relative to the institution's positions, so it is not a strong signal in either direction.
What is the CRSP stock price today?
The last price recorded on this page for CRISPR Therapeutics AG (CRSP) is $57.34, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CRSP price target?
The analyst consensus price target for CRISPR Therapeutics AG (CRSP) is $67.83 (range $55.00 to $80.00, median $68.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (79 figures)
The 79 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Baarerstrasse 14, ZUG | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Baarerstrasse 14, Zug, ZG, 6300, CH". |
FMP — 71 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 9, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $57.34 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:34.278Z. | |
px.change | Change on the day | +3.45% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.53B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:01.000Z. Captured from FMP at 2026-10-05T21:44:32.866Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.91 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $10M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $44.12–$78.48 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 1.70M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.76 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Samarth Kulkarni | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Shaun Foy — Co-Founder | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 393 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $913.08M, net result $377.66M; FY2022 revenue $440,000, net result −$650.17M; FY2023 revenue $370.00M, net result −$153.61M; FY2024 revenue $35.00M, net result −$366.25M; FY2025 revenue $3.51M, net result −$581.60M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Grant $3.51M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $64.95M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $15.45M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$114.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $1.46M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $68.57M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $17.18M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$130.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $864,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $77.86M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $18.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$154.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $889,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $58.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $16.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$132.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-03.revenue_estimated | Revenue · estimate — report date 2026-08-03 | $7.45M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_actual | EPS · reported — report date 2026-08-03 | −$0.9400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_estimated | EPS · estimate — report date 2026-08-03 | −$1.1900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_actual | Revenue · reported — report date 2026-05-04 | $1.46M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_estimated | Revenue · estimate — report date 2026-05-04 | $6.06M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_actual | EPS · reported — report date 2026-05-04 | −$1.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_estimated | EPS · estimate — report date 2026-05-04 | −$1.1896 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-12.revenue_actual | Revenue · reported — report date 2026-02-12 | $864,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-12.revenue_estimated | Revenue · estimate — report date 2026-02-12 | $4.72M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-12.eps_actual | EPS · reported — report date 2026-02-12 | −$1.3700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-12.eps_estimated | EPS · estimate — report date 2026-02-12 | −$1.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.revenue_actual | Revenue · reported — report date 2025-11-10 | $889,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.revenue_estimated | Revenue · estimate — report date 2025-11-10 | $9.12M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.eps_actual | EPS · reported — report date 2025-11-10 | −$1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.eps_estimated | EPS · estimate — report date 2025-11-10 | −$1.2600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $2.36B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$83.50M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $783.75M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.06× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$83.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$108.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$3.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$500,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$92.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$520,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$84.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$70,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $55.00 – $80.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $67.83 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $68.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 23 transactions · 0 purchases, 3 sales, 20 other transactions · 13 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 80.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 80.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 558 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 528 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Ark Investment Management LLC — shares in provider snapshot | 9,460,939 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 8,348,977 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Orbis Allan Gray Ltd — shares in provider snapshot | 5,449,161 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Capital World Investors — shares in provider snapshot | 4,749,525 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | State Street Corp — shares in provider snapshot | 4,321,666 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-21 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.84 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -30.9% · ROA -20.9% · current ratio 17.96 · earnings yield -10.9% · free-cash-flow yield -7.6% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 2.34× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $2.36B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-03.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.9400) with the recorded estimate (−$1.1900) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 21 of 100 · Weak · pillars 16 / 56 / 44 / 11 / 62 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 21 (stored snapshot Oct 5, 2026) → 21 (current publication computed Oct 6, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-03. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-03.revenue_estimated,earn.history.depth.2026-08-03.eps_actual.comparison,earn.history.depth.2026-08-03.eps_actual,earn.history.depth.2026-08-03.eps_estimated,earn.history.depth.2026-05-04.revenue_actual,earn.history.depth.2026-05-04.revenue_estimated,earn.history.depth.2026-05-04.eps_actual,earn.history.depth.2026-05-04.eps_estimated,earn.history.depth.2026-02-12.revenue_actual,earn.history.depth.2026-02-12.revenue_estimated,earn.history.depth.2026-02-12.eps_actual,earn.history.depth.2026-02-12.eps_estimated,earn.history.depth.2025-11-10.revenue_actual,earn.history.depth.2025-11-10.revenue_estimated,earn.history.depth.2025-11-10.eps_actual,earn.history.depth.2025-11-10.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash runway cross-check (ours) | Years: 5.9; Method: cash and short-term investments of $2364.4M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($403.1M per year); Reaches: 2032-05; Cash basis: cash and short-term investments; Cash: $2.36B; Annualized cash use: $403.10M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-03 | FMP | Financial Modeling Prep (FMP) earnings |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 17.85; Current ratio: 17.85; Debt to equity: 0.45; Net margin: -3,368.7%; Return on assets: -17%; Return on equity: -24.4% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash, investments and debt | Total debt: $783.75M; Liquidity basis: cash and short-term investments; Total liabilities: $904.22M; Cash and short-term investments: $2.36B; Cash and investments: $2.36B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Employees | Count: 393 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-31 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Insider transactions, last 180 days | Net shares: 561,175; Window days: 180; Price low: $46.24; Clustered days: 2026-03-20; 2026-03-23; 2026-05-29; 2026-06-05; Price high: $55.62; Buy transactions: 0; Distinct insiders: 14; Sell transactions: 4; Other transactions: 30; Total transactions: 34; Other transaction types: G-Gift: 1, A-Award: 21, M-Exempt: 8; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-08-07 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Institutional ownership (13F) | Holders: 557; Quarter: 2026-06-30; Ownership: 80.2%; Holders previous quarter: 528; Ownership previous quarter: 80.3 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
Data provided for informational purposes only.
ETFs that hold CRSP
Funds in our ETF coverage that list CRSP among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ARK Innovation ETF (ARKK) | 4.73% |